Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
25.77
+0.49 (1.94%)
Mar 9, 2026, 2:23 PM EDT - Market open
Zenas BioPharma Employees
Zenas BioPharma had 130 employees as of December 31, 2024.
Employees
130
Change
n/a
Growth
n/a
Revenue / Employee
$115,385
Profits / Employee
-$1,460,762
Market Cap
1.38B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Capricor Therapeutics | 160 |
| Monte Rosa Therapeutics | 147 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 106 |
| Savara | 59 |
| MBX Biosciences | 43 |
ZBIO News
- 16 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewsWire
- 4 weeks ago - Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 7 weeks ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 2 months ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
- 2 months ago - Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha